新型降脂药物的研究进展

doi:10.3969/j.issn.1004-583X.2025.09.013

摘要/Abstract

摘要：

血脂是血液中脂类物质的统称,在维持人体正常生理功能方面发挥着关键作用。血脂水平异常与诸多疾病(心、脑血管疾病、肥胖、糖尿病等代谢性疾病)的发生、发展紧密相关,其中最为重要的是以冠状动脉粥样硬化为主的心血管疾病。因此,积极控制血脂水平,对于降低心血管疾病的发生风险、改善患者预后具有至关重要的作用。本文旨在系统、全面地梳理新型降脂药物的研究进展,为临床血脂管理提供更为科学、精准的理论指导。

中图分类号:

R541

李颖, 丛晓强, 刘佳. 新型降脂药物的研究进展[J]. 临床荟萃, 2025, 40(9): 850-854.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://www.lchc.cn/CN/10.3969/j.issn.1004-583X.2025.09.013

https://www.lchc.cn/CN/Y2025/V40/I9/850

参考文献 32

[1]	Banach M, Surma S, Toth PP, et al. 2023: The year in cardiovascular disease-the year of new and prospective lipid lowering therapies. Can we render dyslipidemia a rare disease by 2024?[J]. Arch Med Sci, 2023, 19(6):1602-1615.doi: 10.5114/aoms/174743. eCollection 2023.
[2]	国家心血管病中心. 中国心血管健康与疾病报告2021[M]. 北京: 科学出版社, 2022.
[3]	中国血脂管理指南修订联合专家委员会. 中国血脂管理指南(基层版2024年)[J]. 中华心血管病杂志, 2024, 52(4):330-337.doi:10.3760/cma.j.cn112148-20240102-00002.
[4]	Xu Q, Deng Y, Xiao J, et al. Three musketeers for lowering cholesterol : Statins, ezetimibe and evolocumab[J]. Curr Med Chem, 2021, 28(5):1025-1041.doi: 10.2174/0929867327666200505091738.
[5]	Pirillo A, Catapano AL. New insights into the role of bempedoic acid and ezetimibe in the treatment of hyper-cholesterolemia[J]. Curr Opin Endocrinol Diabetes Obes, 2022, 29(2):161-166. doi: 10.1097/MED.0000000000000706. pmid: 34980867
[6]	Lee J, Lee SH. Expanding the therapeutic landscape:Ezetimibe as non-statin therapy for dyslipidemia[J]. Korean J Intern Med, 2023, 38(6):797-809.doi: 10.3904/kjim.2023.243.
[7]	Hummelgaard S, Vilstrup JP, Gustafsen C, et al. Targeting PCSK9 to tackle cardiovascular disease[J]. Pharmacol Ther, 2023, 24(9):108-114. doi: 10.1016/j.pharmthera.2023.108480.
[8]	Rosenson RS, Hegele RA, Fazio S, et al. The evolving future of PCSK9 inhibitors[J]. J Am Coll Cardiol, 2018, 72(3):314-329.doi: 10.1016/j.jacc.2018.04.054. pmid: 30012326
[9]	Zhao L, Liu Y, Cao Z, et al. Application value of PCSK9 inhibitor in cardiovascular high risk patients: A meta-analysis[J]. Iran J Public Health, 2023, 52(5):903-912.doi: 10.18502/ijph.v52i5.12707. pmid: 37484718
[10]	Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. 2022 ACC expert consensus decision pathway on the role of nonstatin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: A report of the American College of Cardiology Solution Set Oversight Committee[J]. J Am Coll Cardiol, 2022, 80(14):1366-1418.doi: 10.1016/j.jacc.2022.07.006. pmid: 36031461
[11]	Blom DJ, Harada-Shiba M, Rubba P, et al. Efficacy and safety of alirocumab in adults with homozygous familial hypercholesterolemia: The ODYSSEY HoFH trial[J]. J Am Coll Cardiol, 2020, 76(2):131-142.doi: 10.1016/j.jacc.2020.05.027.
[12]	Pérez de Isla L, Díaz-Díaz JL, Romero MJ, et al. Alirocumab and coronary ath erosclerosis in asymptomatic patients with familial hypercholesterol emia: The ARCHITECT study[J]. Circulation, 2023, 147:1436-1443. doi: 10.1161/CIRCULATIONAHA.122.062557.
[13]	Giugliano RP, Pedersen TR, Park JG, et al. FOURIER Investigators. Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: A prespecified secondary analysis of the FOURIER trial[J]. Lancet, 2017, 390(10106):1962-1971.doi: 10.1016/S0140-6736(17)32290-0. pmid: 28859947
[14]	Kodera S, Kiyosue A, Ando J, et al. Cost-effectiveness analysis of cardiovascular disease treatment in Japan[J]. Int Heart J, 2017, 58(6):847-852. doi: 10.1536/ihj.17-365. pmid: 29151496
[15]	Ray KK, Wright RS, Kallend D, et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol[J]. N Engl J Med, 2020, 382(16):1507-1519. doi: 10.1056/NEJMoa1912387.
[16]	Zhang Y, Chen H, Hong L, et al. Inclisiran: A new generation of lipid-lowering siRNA therapeutic[J]. Front Pharmacol, 2023, 14:126-132.doi:10.3389/fphar.2023.1260921.
[17]	Ray KK, Kallend D, Leiter LA, et al. Effect of inclisiran on lipids in primary prevention: The ORION-11 trial[J]. Eur Heart J, 2022, 43(48):5047-5057. doi: 10.1093/eurheartj/ehac615. pmid: 36331315
[18]	Huo Y, Lesogor A, Lee CW, et al. Efficacy and safety of inclisiran in Asian patients: Results from ORION-18[J]. JACC Asia, 2023, 4(2):123-134.doi: 10.1016/j.jacasi.2023.09.006.
[19]	Nissen SE, Linnebjerg H, Shen X, et al. Lepodisiran, an extended-duration short interfering RNA targeting lipoprotein(a): A randomized dose-ascending clinical trial[J]. JAMA, 2023, 330(21):2075-2083. doi: 10.1001/jama.2023.21835. pmid: 37952254
[20]	Endo M, Kami M. Lepodisiran for elevated lipoprotein(a)[J]. JAMA, 2024, 331(16):1417. doi: 10.1001/jama.2024.0845.
[21]	Luo F, Das A, Khetarpal SA, et al. ANGPTL3 inhibition, dyslipidemia, and cardiovascular diseases[J]. Trends Cardiovasc Med, 2024, 34(4):215-222.doi: 10.1016/j.tcm.2023.01.008.
[22]	Kosmas CE, Bousvarou MD, Tsamoulis D, et al. Novel RNA-based therapies in the management of dyslipidemias[J]. Int J Mol Sci, 2025, 26(3):1026. doi: 10.3390/ijms26031026.
[23]	Chebli J, Larouche M, Gaudet D. APOC3 siRNA and ASO therapy for dyslipidemia[J]. Curr Opin Endocrinol Diabetes Obes, 2024, 31(2):70-77.doi: 10.1097/MED.0000000000000857. pmid: 38334488
[24]	Tselepis AD. Treatment of Lp(a): Is it the future or are we ready today[J]. Curr Atheroscler Rep, 2023, 25(10):679-689.doi: 10.1007/s11883-023-01141-y.
[25]	Marcovina SM, Viney NJ, Hughes SG, et al. Temporal variability in lipoprotein(a) levels in patients enrolled in the placebo arms of IONIS-APO(a)Rx and IONIS-APO(a)-LRx antisense oligonucleotide clinical trials[J]. Clin Lipidol, 2018, 12(1):122-129.doi: 10.1016/j.jacl.2017.10.024.
[26]	Jang AY, Lim S, Jo SH, et al. New trends in dyslipidemia treatment[J]. Circ J, 2021, 85(6):759-768.doi: 10.1253/circj.CJ-20-1037. pmid: 33177309
[27]	Nissen SE, Lincoff AM, Brennan D, et al. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients[J]. N Engl J Med, 2023, 388(15):1353-1364.doi: 10.1056/NEJMoa2215024.
[28]	Ogita M, Suwa S, Ebina H, et al. Off-hours presentation does not affect in-hospital mortality of Japanese patients with acute myocardial infarction: J-MINUET substudy[J]. J Cardiol, 2017, 70(6):553-558. doi: 10.1016/j.jjcc.2017.05.006. pmid: 28684209
[29]	Ray KK, Bays HE, Catapano AL, et al. Safety and efficacy of bempedoic acid to reduce LDL cholesterol[J]. N Engl J Med, 2019, 380(11):1022-1032.doi: 10.1056/NEJMoa1803917.
[30]	Kersten S. ANGPTL3 as therapeutic target[J]. Curr Opin Lipidol, 2021, 32(6):335-341. doi: 10.1097/MOL.0000000000000789. pmid: 34581310
[31]	Sosnowska B, Adach W, Surma S, et al. Evinacumab, an ANGPTL3 inhibitor, in the treatment of dyslipidemia[J]. J Clin Med, 2022, 12(1):168.doi: 10.3390/jcm12010168.
[32]	Remblay F, Xiong Q, Shah SS, et al. A potent epigenetic editor targeting human PCSK9 for durable reduction of low-density lipoprotein cholesterol levels[J]. Nat Med, 2025, 31(4):1329-1338.doi: 10.1038/s41591-025-03508-x.

新型降脂药物的研究进展

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 32

相关文章 15

编辑推荐

Metrics

本文评价

[1]	尤佳伟, 安艳新, 吕佳宁, 高晓红, 胡丽艳, 单婕, 陈琳. 中国45岁及以上人群社交活动与心脏疾病的相关性[J]. 临床荟萃, 2025, 40(8): 689-693.
[2]	刘洋, 梁燕敏. 新型降脂药物的最新研究进展[J]. 临床荟萃, 2025, 40(8): 736-741.
[3]	曹淑风, 杨昌林. 二十碳五烯酸在心血管疾病中的相关研究及临床应用[J]. 临床荟萃, 2025, 40(6): 564-569.
[4]	张雪, 王俊祥. 类风湿关节炎共病的研究进展[J]. 临床荟萃, 2025, 40(1): 86-89.
[5]	张中楼, 崔坤, 孟晋启. 运动保护心血管系统的研究进展[J]. 临床荟萃, 2024, 39(9): 855-860.
[6]	马剑楠, 陶杰, 桑大森, 吴寿岭, 张旗. 尿转铁蛋白与2型糖尿病人群新发心血管疾病的关系[J]. 临床荟萃, 2024, 39(8): 700-705.
[7]	庞樱容, 孙欣. sST2在心血管疾病中作用的研究进展[J]. 临床荟萃, 2024, 39(5): 460-465.
[8]	王玉伟, 金迪, 付永兴, 刘志刚. 系统性红斑狼疮相关动脉粥样硬化研究进展[J]. 临床荟萃, 2024, 39(11): 1052-1056.
[9]	顾天舒, 梁雪, 蔡嘉庚, 李广平. m6A RNA甲基化修饰在心血管疾病中的进展[J]. 临床荟萃, 2023, 38(8): 743-748.
[10]	王宁, 李勇. 簇集蛋白在心血管疾病中的研究进展[J]. 临床荟萃, 2022, 37(9): 842-845.
[11]	张舒, 包云, 陈芳, 单清. 人体成分分析及人体测量对绝经后女性血脂异常的预测价值[J]. 临床荟萃, 2022, 37(8): 708-712.
[12]	张怡, 崔晓冉, 杨晓红. 单核细胞/高密度脂蛋白胆固醇比值在心血管疾病中研究进展[J]. 临床荟萃, 2022, 37(6): 551-555.
[13]	张磊, 娄海东, 智昱, 亓树莹. PCSK9抑制剂对动脉粥样硬化性心血管疾病有效性及安全性的meta分析[J]. 临床荟萃, 2022, 37(12): 1074-1080.
[14]	杨瑞, 刘宇宏. 类风湿关节炎患者血脂水平与心血管疾病风险相关研究进展[J]. 临床荟萃, 2022, 37(1): 92-96.
[15]	叶蒙蒙, 李旎, 徐国栋, 邵国丰. miR-361在心血管疾病的研究进展[J]. 临床荟萃, 2021, 36(9): 843-849.